SEC Company Response from Veraxa Biotech AG - Post de-SPAC (VRXA) — Feb 13, 2026
Veraxa Biotech AG - Post de-SPAC
Date: Feb. 13, 2026 · CIK: 0002079109 · Accession: 0001829126-26-001328
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289108
Letter
VERAXA BIOTECH HOLDING AG
Talacker 35
8001 Zurich, Switzerland
February 13, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
Re: Veraxa Biotech Holding AG (the “ Registrant ”) Registration Statement on Form F-4 (File No. 333-289108) (the “ Registration Statement ”)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Registrant, Voyager Acquisition Corp. and Veraxa Biotech AG (each a “ Co-Registrant ”), respectfully request that the effective date of the Company’s above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 p.m. ET on February 17, 2026, or as soon thereafter as is practicable.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform Andrew M. Tucker of Duane Morris LLP, by telephone at (202) 776-5248 or by email at atucker@duanemorris.com or Michael J. Blankenship of Winston & Strawn LLP, by telephone at (713) 651-2600 or by email at mblankenship@winston.com. The Registrant and the Co-Registrants hereby authorize Mr. Tucker or Mr. Blankenship to orally modify or withdraw this request for acceleration.
Very truly yours,
VERAXA BIOTECH HOLDING AG
Show Raw Text
CORRESP 1 filename1.htm VERAXA BIOTECH HOLDING AG Talacker 35 8001 Zurich, Switzerland February 13, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Veraxa Biotech Holding AG (the “ Registrant ”) Registration Statement on Form F-4 (File No. 333-289108) (the “ Registration Statement ”) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Registrant, Voyager Acquisition Corp. and Veraxa Biotech AG (each a “ Co-Registrant ”), respectfully request that the effective date of the Company’s above-referenced Registration Statement be accelerated so that the same will become effective at 5:00 p.m. ET on February 17, 2026, or as soon thereafter as is practicable. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform Andrew M. Tucker of Duane Morris LLP, by telephone at (202) 776-5248 or by email at atucker@duanemorris.com or Michael J. Blankenship of Winston & Strawn LLP, by telephone at (713) 651-2600 or by email at mblankenship@winston.com. The Registrant and the Co-Registrants hereby authorize Mr. Tucker or Mr. Blankenship to orally modify or withdraw this request for acceleration. Very truly yours, VERAXA BIOTECH HOLDING AG By: /s/ Oliver Baumann Name: Oliver Baumann Title: General Manager VOYAGER ACQUISITION CORP. By: /s/ Adeel Rouf Name: Adeel Rouf Title: Chief Executive Officer, President and Director VERAXA BIOTECH AG By: /s/ Christoph Antz Name: Christoph Antz Title: Chief Executive Officer and Co-Founder